New theranostic approach reduces tumor volume and increases survival in NET study

(Society of Nuclear Medicine and Molecular Imaging) A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue ofThe Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news